Jad Fakhry is 10% at NovaBay Pharmaceuticals, Inc. (NBY). They have made 5 open-market trades across 2 companies since 2016, most recently 2025-04-08.
CIK 0001588217
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
5 open-market purchases totalling $229K since 2016, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NBY | BUY | 2025-04-02 | 2025-04-15 | $0.55 | $16K | -2.6% | -3.5% | +14.8% |
| NBY | BUY | 2025-03-18 | 2025-04-15 | $0.62 | $31K | -2.6% | -3.5% | +14.8% |
| NBY | BUY | 2025-02-25 | 2025-04-15 | $0.61 | $30K | -2.6% | -3.5% | +14.8% |
| NBY | BUY | 2025-02-03 | 2025-04-15 | $0.66 | $56K | -2.6% | -3.5% | +14.8% |
| SWSH | BUY | 2016-05-13 | 2016-05-17 | $0.93 | $97K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.